Oncology
Latest news
915 articles · 20 / page
T-DXd Combinations Redefine Therapeutic Boundaries in HER2-Low Metastatic Breast Cancer: Key Findings from DESTINY-Breast08
The DESTINY-Breast08 phase 1b study demonstrates that trastuzumab deruxtecan (T-DXd) combined with chemotherapy, AKT inhibitors, or endocrine therapy is manageable and clinically active in HER2-low metastatic breast cancer, offering new pat
Pegylated Liposomal Doxorubicin Sets New Standard in Refractory Desmoid Tumors: Phase 3 Trial Insights
This Phase 3 trial demonstrates that pegylated liposomal doxorubicin significantly extends progression-free survival and improves response rates in patients with advanced desmoid tumors, offering a potent systemic option for refractory dise
Beyond Breast Cancer: ESR1 Mutations Identified as Prevalent Primary Drivers in NSMP Low-Grade Endometrial Cancer
Results from the UTOLA trial reveal that ESR1 mutations, a hallmark of AI resistance in breast cancer, are present in 22% of metastatic NSMP low-grade endometrial cancer patients before endocrine therapy, suggesting a need for molecular str
SARC031 Trial: Why Combined MEK and mTOR Inhibition Failed to Translate from Mice to Men in MPNST
The SARC031 Phase 2 trial evaluated selumetinib and sirolimus for advanced MPNST. Despite strong preclinical rationale, the combination showed minimal clinical benefit, though correlative studies on cfDNA and PET imaging offer vital insight
Atezolizumab Demonstrates Moderate Efficacy in TMB-High Solid Tumors: Insights from the TAPISTRY Phase II Trial
The Phase II TAPISTRY trial evaluates atezolizumab in patients with high tumor mutational burden (TMB ≥13 or ≥16 mut/Mb), showing an objective response rate of approximately 20-22% across various solid tumors with a manageable safety profil
Potent Immune Activation Fails to Translate into High Response Rates: Lessons from the Cergutuzumab Amunaleukin and Atezolizumab Phase Ib Trial
A Phase Ib study of the IL-2 variant immunocytokine cergutuzumab amunaleukin plus atezolizumab demonstrates manageable safety and robust peripheral immune activation but modest clinical activity in CEA-positive advanced solid tumors.
Limited Efficacy for Cabozantinib and Nivolumab in Advanced Extrapancreatic Neuroendocrine Tumors: Insights from a Phase II Trial
A Phase II trial investigating the combination of cabozantinib and nivolumab in advanced extrapancreatic neuroendocrine tumors (epNETs) failed to meet its primary objective response rate endpoint, despite high rates of stable disease, highl
Breakthroughs in Prostate Cancer: Insights from the MetaCURE Multi-Modal Trial
The MetaCURE trial demonstrates that combining surgery, radiation, and advanced hormonal therapies can achieve deep responses in high-risk prostate cancer, paving the way for faster drug development through intermediate clinical endpoints.
Integrating Automated Radiomics with Serum Biomarkers Redefines Risk Stratification in Metastatic Castration-Resistant Prostate Cancer
This article explores how novel automated imaging tools, combined with clinical biomarkers, enhance risk stratification in mCRPC, while also reviewing the pivotal OS data from abiraterone and enzalutamide trials that inform contemporary tre
THAG Regimen Shows High Efficacy as Conversion Therapy for Pancreatic Cancer: New Phase II Trial Results
A Phase II trial demonstrates that the THAG regimen—combining immunotherapy, radiotherapy, and chemotherapy—significantly improves R0 resection rates and survival in patients with BRPC and LAPC, supported by IL-6 and ctDNA biomarker insight
HER2DX Genomic Testing Outperforms Traditional Histopathology in Predicting Neoadjuvant Therapy Response for HER2-Positive Breast Cancer
This comprehensive analysis validates the HER2DX genomic assay as a robust tool that reflects tumor biology and independently predicts pathologic complete response, offering clinicians a precise instrument for personalizing treatment in ear
Targeting the PI3K/AKT Pathway: Ipatasertib Shows Promise as Maintenance Therapy for PIK3CA-Mutated, HER2-Positive Metastatic Breast Cancer
The Phase 1b SOLTI-1507 IPATHER trial demonstrates that adding the AKT inhibitor ipatasertib to trastuzumab and pertuzumab is a safe and clinically active maintenance strategy for patients with PIK3CA-mutated HER2-positive metastatic breast
Zanidatamab-Based Triplet Therapy Redefines Survival Expectations in HER2-Positive Gastric Cancer: Insights from a Phase 1b/2 Study
A phase 1b/2 trial reveals that combining the bispecific antibody zanidatamab with tislelizumab and chemotherapy yields a 75.8% response rate and an impressive median overall survival of 32.4 months in first-line HER2-positive gastric and g
Synergistic Potential and Hematologic Hurdles: Sapacitabine and Olaparib in BRCA1/2-Mutated Metastatic Breast Cancer
A Phase Ib study of sapacitabine and olaparib in gBRCA-mutated metastatic breast cancer showed a 50% objective response rate and 9.7-month median PFS. While significant hematological toxicities limited dose escalation, the combination demon
Palbociclib, Trastuzumab, and Endocrine Therapy Significantly Extend Progression-Free Survival in PAM50 Luminal HER2-Positive Advanced Breast Cancer: Results from the SOLTI-1303 PATRICIA Trial
The Phase II SOLTI-1303 PATRICIA trial (Cohort C) demonstrates that a triplet regimen of palbociclib, trastuzumab, and endocrine therapy significantly improves progression-free survival compared to physician’s choice treatments in pretreate
Biomarkers of Benefit: tTMB and MSI Status Redefine Immunotherapy Success in Metastatic Castration-Resistant Prostate Cancer
A large-scale clinico-genomic study confirms that both tissue-based TMB and MSI-H independently predict significantly improved outcomes for ICI therapy in metastatic castration-resistant prostate cancer, while also validating blood-based MS
FET-rearranged Myoepithelial Tumors: Why Epigenetics Demands a Shift from Carcinoma to Sarcoma Classification
A landmark study reveals that FET-rearranged myoepithelial tumors are epigenetically distinct from PLAG1-rearranged salivary and adnexal variants, suggesting they are closer to sarcomas than carcinomas, with significant clinical implication
Antiviral Prophylaxis Levels the Playing Field: Safe ICI Use in High-Viral Load HBV-HCC Patients
A prospective study demonstrates that concurrent antiviral prophylaxis effectively mitigates HBV reactivation risk in HCC patients treated with PD-1/L1 inhibitors, regardless of baseline viral load, challenging traditional clinical trial ex
MSI-H and TMB-H as Independent Predictors: Refining Immunotherapy Selection in Metastatic Castration-Resistant Prostate Cancer
A large-scale clinico-genomic study demonstrates that both tissue-based MSI-H and TMB-H status independently predict superior outcomes for immune checkpoint inhibitors in mCRPC, while validating blood-based MSI as a viable alternative for p
Biomarker-Driven Precision in Low-Grade Serous Ovarian Cancer: pERK and MAPK Mutations as Predictors of Trametinib Efficacy
Highlights Background: The Unique Challenge of Low-Grade Serous Ovarian Cancer Low-grade serous ovarian carcinoma (LGSOC)...
Browse by specialty
Open language-specific specialty feeds and department pages.